Cerebain Biotech Closes Share Exchange Agreement With PKG

COSTA MESA, Calif.–(BUSINESS WIRE)–Cerebain Biotech Corp. today announced that it has closed the Share Exchange Agreement with PKG thereby having total control and ownership of PKG.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

About PKG

PKG was established in 1989 and is a privately held corporation based in Meridian, ID. PKG, specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps raise your company to the next level by leveraging our engineering and technology integration skills across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all of their product development and manufacturing needs. Besides our expertise in system-level devices and human-machine interfaces, PKG also offers incubation and acceleration services for startup businesses and entrepreneurs. For more information visit, www.pkguis.com